Katelyn Jetelina, MPH PhDan epidemiologist, wife, and mom of two little girls
There was a dose-finding trial done by Eussen et al
PubMed Sikiric, P., Hahm, K.B., Blagaic, A.B., Tvrdeic, A., Pavlov, K.H., Petrovic, A., Kokot, A., Gojkovic, S., Krezic, I., Drmic, D., Rucman, R., & Seiwerth, S
Well build a complete, honest plan around your goals foundations first, with the BPC-157 / TB-500 combination considered only if it genuinely fits
Short non-diabetic data support remaining at 2.5 mg when weight and insulin-resistance markers are already moving and tolerability favors a hold. The label still positions 2.5 mg as the starter before 5 mg, so it is a defensible low-dose floor for selected users rather than a replacement for the 5 mg obesity-trial floor